218 related articles for article (PubMed ID: 32343604)
1. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida DVP; Fong L; Rettig MB; Autio KA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
3. Understanding the tumor-immune microenvironment in prostate cancer.
Dong L; Myers KV; Pienta KJ
Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
[TBL] [Abstract][Full Text] [Related]
4. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
5. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Koo KC
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
7. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
8. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
Reva BA; Omelchenko T; Nair SS; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
[TBL] [Abstract][Full Text] [Related]
9. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
10. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract][Full Text] [Related]
11. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
12. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
14. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
15. Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE; Odunsi K; Coukos G
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibition in Prostate Cancer.
Nicholson LT; Fong L
Trends Cancer; 2020 Mar; 6(3):174-177. PubMed ID: 32101720
[TBL] [Abstract][Full Text] [Related]
17. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
18. The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few.
F Slovin S
Immunotherapy; 2020 Mar; 12(4):219-221. PubMed ID: 32172641
[No Abstract] [Full Text] [Related]
19. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
Siewe N; Friedman A
PLoS One; 2022; 17(1):e0262453. PubMed ID: 35015785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]